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Introduction
Mdm2 is well characterized as the major negative regulator 
of the tumor suppressor p53.1-3 The C terminus of Mdm2 
confers intrinsic E3 ubiquitin ligase activity, which promotes 
the ubiquitination and degradation of p53.4-7 Mdm2 is a 
transcriptional target of p53, forming a regulatory feedback loop 
between Mdm2 and p53 to maintain cellular homeostasis.4,8-11 
The importance of Mdm2 in proper p53 regulation makes the 
understanding of its own regulation of critical concern. In order 
for the Mdm2-p53 feedback loop to function properly, tight 
regulation of Mdm2 degradation is essential. Previous in vitro and 
overexpression studies have demonstrated that Mdm2 regulates 
its own degradation by autoubiquitination, targeting itself for 
proteasome-mediated degradation.12,13 However, recent studies 
of Mdm2C462A/C462A knock-in mice have challenged the Mdm2 
autoubiquitination dogma. In Mdm2C462A/C462A mouse embryonic 
fibroblasts (MEFs), the mutant Mdm2C462A protein is degraded 
as rapidly as wild-type Mdm2 while p53 degradation is blocked, 
indicating that Mdm2 E3 ligase activity is not required for its own 
degradation when endogenously expressed,14,15 and suggesting 
that other E3 ubiquitin ligases regulate Mdm2 stability.14,15
In light of this in vivo data, the potential for an outside 
E3 ubiquitin ligase to function in Mdm2 regulation has been 
more expressly studied. The Cullin1/β-TRCP E3 ubiquitin 
ligase complex was identified to interact with Mdm2, and this 
interaction was demonstrated to lead to the poly-ubiquitination 
and degradation of Mdm2.16 However, the regulation of 
Mdm2:Cullin1/β-TRCP interaction suggests that this 
interaction only occurs following DNA damage. Furthermore, 
knockdown of Cullin1-βTRCP does not block p53 activation; 
instead, it affects the regulation of Mdm2 and p53 during 
the recovery of cells to basal conditions following exposure to 
stress.16 More recently, NEDD4–1 was biochemically identified 
to contribute to the regulation of Mdm2 protein stability in cells 
by functioning as an E3 ligase; however, NEDD4–1 catalyzes 
the formation of K63-type polyubiquitin chains on Mdm2 that 
are distinct from the K48-type polyubiquitin chains typically 
required for proteasomal degradation.17 Notably, K63-type 
polyubiquitination by NEDD4–1 competes with K48-type 
polyubiquitination of Mdm2 in cells, and, as a result, NEDD4–
1-mediated ubiquitination stabilizes Mdm2. Our study was 
designed to identify E3 ubiquitin ligases responsible for the 
regulation of Mdm2 stability under physiological conditions.
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the Mdm2 proto-oncoprotein is the primary negative regulator for p53. While it is believed that Mdm2 degradation is 
regulated via its own e3 ubiquitin ligase activity, recent development of knock-in mouse models demonstrates that Mdm2 
e3 ligase function is dispensable for self-degradation in vivo. Here, we show that the anaphase-promoting complex/
cyclosome (ApC/C) is an e3 ubiquitin ligase for Mdm2 degradation. We demonstrate that ApC2, a scaffold subunit of 
ApC/C, binds to Mdm2 and is required for Mdm2 polyubiquitination and proteasomal degradation. Downregulation 
of ApC2 by RNAi results in transcription-independent accumulation of Mdm2 and attenuation of stress-induced p53 
stabilization, leading to decreased senescence and increased cell survival. Furthermore, ApC2 expression is frequently 
downregulated in human cancers; in tumor cell lines, ApC2 downregulation correlates with Mdm2 overexpression. our 
study shows the regulation of Mdm2 by the e3 ubiquitin ligase ApC/C and has important therapeutic implications for 
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Results
Mdm2 E3 ubiquitin ligase function is dispensable for Mdm2 
self-degradation under physiological conditions
To examine the role of Mdm2 E3 ligase function in Mdm2 
degradation in vivo, we compared the degradation dynamics 
of Mdm2 in MEFs expressing wild-type (WT) Mdm2 or E3 
ligase inactive mutant Mdm2. We generated 2 Mdm2 knock-in 
mouse models with inactivated Mdm2 E3 ubiquitin ligase 
activity toward p53: Mdm2Y487A (corresponding to human 
Mdm2Y489A)18 and Mdm2C462A (corresponding to human 
Mdm2C464A).14 Both  mutated Mdm2 genes are under the control 
of the native promoter and hence result in physiological levels of 
Mdm2 expression. While both the Mdm2Y487A and Mdm2C462A 
proteins display disrupted E3 ubiquitin ligase activity for p53, 
the mechanism of disruption in each of these mutants is unique. 
The Mdm2Y487A mutation is C-terminal of the RING domain, 
in a region previously demonstrated to be critical for Mdm2 
E3 ubiquitin ligase activity toward p53; however, this mutation 
retains an intact RING domain.18 In contrast, the Mdm2C462A 
mutation affects one of the 4 critical cysteine residues responsible 
for maintaining the RING domain structure; disruption of the 
Mdm2 RING domain structure results in the loss of E3 ubiquitin 
ligase activity.18 Because the Mdm2C462A mutation results in 
early embryonic lethality in homozygous mice, we crossed 
Mdm2C462A/+ mice with mice expressing inducible p53ERTAM 
(p53ER hereafter); the inducible nature of the p53ER fusion 
protein allows for generation of mice and MEFs with inactive 
p53.19 The addition of 4-Hydroxytamoxifen (4-OHT) activates 
p53ER to allow for transactivation of Mdm2 and the study of 
Mdm2 dynamics in the Mdm2C462A/C462A background. In the 
presence of 4-OHT, the half-life of p53ER was approximately 
30 min, and the half-life of Mdm2 approximately 15 min in 
Mdm2+/+;p53ER/- MEFs (Fig. 1A). The disruption of Mdm2 
E3 ligase activity greatly extended the half-life of p53ER, as 
observed in Mdm2Y487A/Y487A ;p53ER/- and Mdm2C462A/C462A;p53ER/- 
MEFs (Fig. 1B and C). These results support previous findings 
and indicate that in vivo the Mdm2Y487A and Mdm2C462A mutant 
proteins have indeed lost E3 ubiquitin ligase activity for p53 
degradation.
To evaluate the importance of Mdm2 E3 ligase function in the 
degradation of Mdm2 itself, we assessed the half-life of Mdm2 
in Mdm2+/+;p53ER/-, Mdm2Y487A/Y487A;p53ER/- and Mdm2C462A/
C462A;p53ER/- MEFs. Despite disrupting p53 degradation, 
Mdm2Y487A and Mdm2C462A protein itself was degraded normally 
when compared with WT Mdm2 (Fig. 1A–C). Furthermore, 
treatment with the proteasome inhibitor MG-132 led to similar 
stabilization of WT Mdm2, Mdm2Y487A, and Mdm2C462A 
(Fig. 1D), suggesting that each of these proteins is degraded at 
a similar rate in a proteasome-dependent manner. To eliminate 
the possible aberrant effect of p53ER on transcriptional 
regulation of Mdm2, Mdm2+/+;p53−/−, Mdm2Y487A/Y487A;p53−/−, 
and Mdm2C462A/C462A;p53−/− mice were generated, and MEFs 
were isolated and similarly subjected to MG-132 treatment. 
In the absence of p53, MG-132 treatment resulted in a similar 
level of Mdm2 stabilization, regardless of the E3 ligase status 
of Mdm2 and consistent with observations made in the p53ER/- 
genetic background (Fig. 1E). These results suggest that while 
Mdm2 E3 ligase function is necessary for the degradation of p53, 
under physiological conditions, this function is dispensable for 
proteasome-dependent degradation of Mdm2.
In light of the normal, proteasome-dependent Mdm2 
degradation dynamics observed in Mdm2 E3 inactive MEFs, we 
postulated that an alternative E3 ubiquitin ligase(s) is responsible 
for Mdm2 degradation under physiological conditions. To test 
this hypothesis, we used an in vitro ubiquitin ligase assay to 
assess the E3 ubiquitin ligase activity of HeLa cell lysate toward 
bacterial purified Mdm2 protein. Consistent with previous 
studies, and similar to most other RING finger domain-
containing proteins that confer E3 ligase activity, purified 
WT Mdm2 protein demonstrated intrinsic autoubiquitination 
activity in the in vitro ubiquitin ligase assay; in contrast, 
Mdm2C464A mutant protein does not demonstrate intrinsic 
autoubiquitination activity (Fig. 1F).12,20 Interestingly, following 
the addition of HeLa cell lysate to the Mdm2C464A protein reaction 
samples, strong polyubiquitin chain formation was observed 
(Fig. 1F). The ability for Mdm2C464A to be polyubiquitinated in 
the presence of HeLa cell lysate suggests that an E3 ubiquitin 
ligase(s) capable of polyubiquitinating Mdm2 is present in the 
lysate. To rule out the possibility that WT Mdm2 present in the 
HeLa lysate is responsible for the observed polyubiquitination of 
Mdm2C464A, we assessed polyubiquitin chain formation in cell 
lysate isolated from WT, Mdm2+/+;p53−/− and Mdm2−/−;p53−/− 
MEFs. Polyubiquitin chain formation in WT, Mdm2+/+;p53−/− 
and Mdm2−/−;p53−/− MEF cell lysate occurred at similar levels 
(Fig. 1G), indicating that a component in the MEF cell lysates, 
independent of both Mdm2 and p53, is capable of promoting 
Mdm2 polyubiquitination.
We then tested if this polyubiquitin chain formation is 
dependent on E1 and E2 supplied in vitro by individually removing 
each of these components. Polyubiquitin chain formation 
was dependent on E2 supplied in vitro, but HeLa cell lysates 
contained sufficient E1 ubiquitin activating enzyme to support 
the in vitro ubiquitination reaction (Fig. S1A). Furthermore, 
we found that the E3 ubiquitin ligase activity from HeLa cell 
lysate was diminished in the presence of SDS, providing further 
evidence that an enzymatic activity in the HeLa lysate is essential 
for the observed polyubiquitin chain formation (Fig. S1B).
Mdm2 interacts with APC2
Previous studies have indicated that Mdm2 protein levels 
oscillate with the cell cycle.16,21 Accordingly, we also found that 
in WT and p53−/− MEFs synchronized by serum starvation, 
Mdm2 protein levels oscillated in a manner correlated with 
cyclin B1 oscillations (Fig. 2A and B). Similar results were also 
observed in U2OS cells synchronized with serum starvation 
(Fig. S2A), and HeLa and HCT116/p53-/- cells synchronized 
by double thymidine block (Fig. S2B and C). Together, these 
results suggest that Mdm2 levels may be regulated throughout 
the cell cycle, presumably by a member of the Cullin family E3 
ubiquitin ligases, in a manner similar to cyclin B1. Furthermore, 
the observed oscillation of Mdm2 in p53-null cells suggests that 
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To test the possibility that a Cullin family E3 ubiquitin 
ligase is responsible for the ubiquitination and degradation of 
Mdm2, we first determined the binding affinity of Cullin family 
E3 ubiquitin ligases with Mdm2 via immunoprecipitation. As 
shown in Figure 2C, Mdm2 interacted with Cullin1 when 
co-overexpressed, consistent with previous studies characterizing 
Cullin1:Mdm2 binding.16 Additionally, we observed Mdm2 
interaction with APC2, a scaffold subunit of APC/C, which is 
a multi-subunit E3 ubiquitin ligase complex that controls the 
degradation of many proteins involved in cell cycle regulation 
(Fig. 2C). Most APC/C substrates oscillate their protein 
levels throughout the cell cycle, including the metaphase–
anaphase transition and mitotic exit.22-24 We confirmed 
APC2:Mdm2 interaction with reciprocal immunoprecipitation 
of ectopically expressed proteins (Fig. 2D and E), as well as with 
immunoprecipitation of endogenous Mdm2 in 293T and H1299 
cells. 293T and H1299 cells express different levels of Mdm2, 
which allowed for correlation of the levels of Mdm2 with the 
levels of APC2 being co-immunoprecipitated (Fig. 2F).
APC2 is important for Mdm2 degradation
To test if APC/C is a physiological E3 ubiquitin ligase for 
Mdm2, we knocked down APC2 in human tumor cell lines 
and examined the levels of Mdm2. Knockdown of APC2 by 
siRNA in both U2OS (p53-positive) and HCT116/p53-/- (p53-
negative) cells led to accumulation of Mdm2 (Figs. 3A and B), 
as well as extension of Mdm2 protein half-life (Figs. S3A and B). 
The limited increase of Mdm2 level upon APC2 knockdown 
suggested that there are other E3 ligase(s), in addition to 
Figure 1. Mdm2 e3 ubiquitin ligase function is dispensable for Mdm2 self-degradation under physiological conditions. (A) Mdm2+/+;p53ER/- MeFs were 
treated with 100 nM 4-oHt for 24 h before treatment with 150 mg/mL cycloheximide. Cell lysates were collected at the indicated times following cyclo-
heximide treatment and p53eR and Mdm2 levels were analyzed by western blot. Actin was used as a loading control. (B) Mdm2C462A/C462A;p53ER/- MeFs were 
treated and analyzed as described in (A). (C) Mdm2Y487A/Y487A;p53ER/- MeFs were treated and analyzed as described in (A). (D) Mdm2+/+;p53ER/-, Mdm2Y487A/
Y487A;p53ER/-, and Mdm2C462A/C462A;p53ER/- MeFs were treated with 25 uM MG-132 for 8 h, as indicated. Mdm2 levels were analyzed by western blot. Actin 
was used as a loading control. (E) Mdm2+/+;p53−/−, Mdm2Y487A/Y487A;p53−/−, and Mdm2C462A/C462A;p53−/− MeFs were treated and analyzed as in (D). (F) An equal 
amount of bacterial purified GSt, GSt-tagged wild-type Mdm2, and GSt-tagged Mdm2C464A protein bound to glutathione beads was incubated with 
e1, e2, and ubiquitin (Ub) with or without addition of HeLa cell lysate for 1 h at 37° C as indicated. Ubiquitin bound to the glutathione bead associated 
materials was analyzed by western blot. (G) experiment is done as in (F), except cell lysate from wild-type (WT), Mdm2+/+;p53−/− (p53−/−), or Mdm2−/−;p53−/− 
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APC2, that degrade Mdm2. To further rule out the possibility 
that the increase in Mdm2 is due to increased transcription of 
Mdm2, rather than decreased degradation, we generated stable 
cell lines expressing GFP-tagged WT Mdm2 (GFP-Mdm2) or 
GFP-tagged Mdm2C464A mutant under the control of the CMV 
promoter. As shown in Figure 3C, knockdown of APC2 by 
siRNA led to a strong accumulation of ectopic GFP-
tagged Mdm2, indicating that the accumulation of 
Mdm2 is independent of transcriptional regulation. 
More importantly, knockdown of APC2 by siRNA 
also led to a strong accumulation of ectopic GFP-
tagged Mdm2C464A, which suggests that the Mdm2 
accumulation observed following downregulation 
of APC2 is independent of Mdm2 E3 ligase activity. 
Disruption of proteasome-mediated degradation 
by MG-132 treatment resulted in an accumulation 
of Mdm2 in U2OS cells transfected with a control 
knockdown siRNA (siCtrl), but did not further stabilize 
Mdm2 in cells transfected with APC2 knockdown 
siRNA (siAPC2), which had higher levels of Mdm2 
prior to MG-132 treatment (Fig. 3E). Together, these 
results indicate that APC2 is important for Mdm2 
degradation in a manner independent of p53 status and 
Mdm2 transcriptional regulation.
APC2 is important for stress-induced p53 
stabilization and activation
Because Mdm2 is the primary regulator of p53, 
mechanisms functioning to regulate Mdm2 will 
inevitably affect p53 function as well. To investigate 
the functional connections of APC2 with p53 activity, 
we examined the effect of downregulation of APC2 on 
p53-induced growth inhibition. We generated MEF 
cells with stable knockdown of APC2 in both WT and 
p53−/− genetic backgrounds. Stable knockdown of APC2 
in the WT, but not p53−/− background, corresponded 
to a higher number of cells displaying flattened 
and enlarged morphology, indicative of senescence. 
Assessment of β-galactosidase activity was utilized to 
determine whether the flattened and enlarged MEF 
cells were indeed senescent. MEFs with APC2 knocked 
down exhibited significantly weaker activity of 
senescence-associated β-galactosidase than control cells 
(Fig. 4A). Additionally, quantitative analysis indicated 
that APC2 knockdown decreased the percentage of 
senescent cells by more than half (Fig. 4A). We then 
analyzed the effect of APC2 knockdown on p53 activity 
by examining p53-dependent transcription using a 
luciferase assay. As shown in Figure 4B, p53-dependent 
activation of the p21 promoter was greatly reduced by 
knockdown of APC2.
To investigate the role of APC2 in the p53 stress 
response, we knocked down APC2 by shRNA in WT 
MEFs and examined cell survival following exposure 
to UV radiation. Under unstressed conditions, APC2 
knockdown did not affect cell survival and resulted 
in a slight increase in p53 levels; however, following 
UV-induced DNA damage, knockdown of APC2 
increased cell survival (Fig. 4C and E–G). This increase 
in cell survival following irradiation was attenuated 
Figure 2. Mdm2 interacts with ApC2. (A) WT MeFs were incubated with DMeM with 
0.1% FBS for 72 h for serum starvation; media was then replaced with fresh DMeM 
with 10% FBS. Cells were harvested at the indicated time points after addition of FBS 
and analyzed by western blot. Actin was used as a loading control. (B) p53−/− MeFs 
were treated, harvested, and analyzed as in (A). (C) 293t cells were transfected with 
FLAG-tagged Mdm2 together with HA-tagged Cullin1 (Cul1), Cullin2 (Cul2), ApC2, 
Cullin3 (Cul3), Cullin4A (Cul4A), or Cullin5 (Cul5) as indicated. Cell lysate was immu-
noprecipitated and immunoblotted with the indicated antibodies. Input represents 
4% of total cell lysate utilized for Ip. (D) 293t cells were transfected as indicated. Cell 
lysate was immunoprecipitated with anti-FLAG and immunoblotted as indicated. 
Input represents 4% of total cell lysate utilized for Ip. Actin was used as a loading 
control for the input. (E) 293t cells were transfected as indicated. Cell lysate was 
immunoprecipitated with anti-Myc antibody and immunoblotted as indicated. 
Input represents 4% of total cell lysate utilized for Ip. Actin was used as a loading 
control for the input. (F) 293t and H1299 cell lysates were immunoprecipitated with 
anti-Mdm2 antibody and immunoblotted as indicated. Input represents 2% of total 
cell lysate utilized for Ip. H1299 cells, with a very low level of Mdm2, were used as a 
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when Mdm2–p53 interaction was disrupted by Nutlin-3 
(Fig. 4D), suggesting that the effect of APC2 on cell survival 
following UV irradiation is p53-dependent.
To determine whether APC2 regulates stress-induced p53 
expression, siRNA was used to knockdown APC2 in U2OS cells, 
followed by treatment with genotoxic agents to challenge the 
cells. Indeed, downregulation of APC2 substantially reduced the 
level of p53 induced by the DNA damaging agents, as observed 
following treatment with UV (Fig. 4E) and doxorubicin 
(Fig. 4F), as well as in response to ribosomal stress, as induced by 
actinomycin D (Fig. 4G). These results indicate that APC2 plays 
an important role in p53 stabilization in response to genotoxic 
stress.
APC2 downregulation correlates with cancer development
To further investigate the physiological relevance of APC2 
regulation of Mdm2, we assessed the expression levels of APC2 
and Mdm2 in various cancer cell lines. Interestingly, JAR and 
SJSA cells expressed very low levels of APC2 and, conversely, 
very high levels of Mdm2 compared with HepG2, MCF7, HeLa, 
A375, U2OS, and H1299 cells, which expressed higher levels 
of APC2 and correspondingly lower levels 
of Mdm2 (Fig. 5A). Of note, in addition to 
expressing low levels of APC2, JAR and SJSA 
cells contain Mdm2 gene amplifications; 
we speculate that the high levels of Mdm2 
observed are the combined effect of low levels 
of APC2 and gene amplification of Mdm2.25,26 
To investigate the clinical relevance of 
variation in APC2 expression, we interrogated 
available tumor data sets for APC2. mRNA 
levels of APC2 were significantly decreased 
in breast, liver, and lymphocyte cancer tissues 
compared with that observed in corresponding 
normal tissue, based on an analysis of the 
Oncomine database (http://www.oncomine.
com) (Fig. 5B). Investigation of breast, 
ovarian, lung, thyroid, liver, and renal cancer 
tissues in The Cancer Genome Atlas (TCGA) 
gene copy data set also revealed that APC2 
gene copy number was decreased compared 
with the gene copy number observed in 
normal tissues (Fig. 5C). The decreased levels 
of APC2 mRNA and gene copy number in 
a variety of cancer types suggest that APC2 
may be clinically relevant in the development 
or progression of cancer.
Discussion
Here, we report that Mdm2 protein stability 
is regulated by the APC/C E3 ubiquitin 
ligase complex through APC2:Mdm2 
interaction. Various biochemical analyses, 
including protein binding and degradation 
assays, as well as functional assays, identify 
Mdm2 as a substrate of APC2. Depletion of APC2 results in 
increased levels of Mdm2, which, in turn, leads to attenuation 
of stress-induced p53 stabilization and increased cell survival. 
Mitotic inhibitors that activate the spindle assembly checkpoint 
by perturbing microtubule function are commonly used in 
the treatment of breast, ovarian, and lung cancers; however, as 
activation of the spindle assembly checkpoint does not suppress 
APC/C activity completely, it is believed that inhibitors directly 
targeting APC/C could provide a better therapeutic method 
for inducing mitotic arrest.27,28 In contrast, our study suggests 
that inhibition of APC/C activity by downregulation of APC2 
can result in oncogenic consequences due to accumulation of 
Mdm2, and the resulting inactivation of p53. In light of this 
finding, the prospect of pharmacologic inhibition of APC/C 
as an anti-cancer therapeutic needs to be carefully reevaluated. 
The observation that APC2 depletion effectively stabilizes 
Mdm2 and leads to inhibition of p53 activation indicates that 
cautious consideration of p53 status should be taken prior 
to the use of cancer treatments targeting APC/C-related 
pathways.
Figure 3. ApC2 is important for Mdm2 degradation. (A) U2oS cells were transfected with con-
trol siRNA (si-Ctrl) or ApC2 siRNA (si-ApC2) for 72 h. Cell lysates were analyzed by western blot-
ting for Mdm2 and ApC2. Actin was used as a loading control. (B) HCt116/p53-/- cells were 
transfected, harvested, and analyzed as in (A). (C) Clonal stable cell lines stably expressing a 
GFp-Mdm2 fusion protein under the control of CMV promoter in U2oS cells were transfected, 
harvested, and analyzed as in (A). (D) Clonal stable cell lines stably expressing a GFp-Mdm2C464A 
fusion protein under the control of CMV promoter in U2oS cells were transfected, harvested, 
and analyzed as in (A). (E) U2oS cells were transfected with control siRNA (si-Ctrl) or ApC2 
siRNA (si-ApC2) for 24 h, cells were then split, and 25 uM MG-132 was added 48 h later. Cells 
were collected at indicated time after MG-132 treatment and analyzed by western blot. Actin 
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Materials and Methods
Cell culture, transfection
All cells were cultured at 37° C, and 5% CO
2
 in DMEM 
supplemented with 10% FBS, 100 U/mL penicillin, and 100 
ug/mL streptomycin. DNA transfections were performed 
using the Calcium phosphate method29 and Fugene-6 
(Promega #E2691, http://www.promega.com/products/
reporter-assays-and-transfect ion/transfect ion-reagents /
fugene-6-transfection-reagent/).
In vitro ubiquitination assay
Bacterial purified GST (Glutathione S-transferase) or GST-
tagged Mdm2C464A bound to glutathione beads (GE Healthcare, 
#17–0756–01 http://www.gelifesciences.com/webapp/wcs/
stores/servlet/productById/en/GELifeSciences/17075601) were 
incubated with 50 ng E1 (UBE1, Millipore, #23–021 https://
www.millipore.com/catalogue/item/23-021-K), 50 ng E2 
(bacterial purified UBCH5C), E3 (cell lysate or APC2 immuno-
complex), 5 ug ubiquitin, and reaction buffer (50 mM TRIS-
HCl pH 8.0, 0.1 M NaCl, 2 mM DTT, 5 mM MgCl2, 2 mM 
Figure 4. ApC2 is important for stress-induced p53 stabilization and activation. (A) WT MeFs infected with non-specific (sh-NS) or ApC2 (sh-ApC2) 
Lentiviral based shRNA were cultured for 12 passages. Cells were stained with β-gal and the percentage of β-gal-positive cells was quantified and plot-
ted. (B) U2oS cells were transiently transfected with control siRNA (si-Ctrl) or ApC2 siRNA (si-ApC2) for 24 h. Cells were split, followed by transfection with 
a pGL3-Basic luciferase reporter plasmid containing the wild-type p21 promoter (p21-Luc), or an empty vector (Vector). Cells were collected 24 h later 
and assayed for luciferase activity. (C) WT MeFs infected with non-specific (sh-NS) or ApC2 (sh-ApC2). Lentiviral-based shRNA were treated with different 
dosages of UV as indicated. Cells were collected 24 h after UV treatment, stained with trypan blue, and counted to determine cell survival. (D) WT MeFs 
infected with non-specific (sh-NS) or ApC2 (sh-ApC2) Lentiviral-based shRNA were treated with 40 J/m2 UV and 8 mM Nutlin-3. Cells were collected 24 
h after treatment, stained with trypan blue, and counted to determine cell survival. (E) U2oS cells were transfected with control siRNA (si-Ctrl) or ApC2 
siRNA (si-ApC2) for 24 h, cells were split, and 15 J/m2 UV was added 48 h later. Cells were collected at the indicated time points after UV treatment, and 
analyzed for Mdm2 and p53 by western blot. Actin was used as a loading control. Bottom: p53 levels were measured by densitometry, normalized to 
actin, and plotted. (F) U2oS cells were treated and analyzed as described in (E) except treatment is 0.5 mg/mL doxorubicin. (G) U2oS cells were treated 
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ATP). Reaction mixes were incubated at 37° C for 1 h, the beads 
were washed with 3 times with washing buffer (50 mM TRIS-
HCl pH 8.0, 0.1 M NaCl, 1 mM DTT, 5 mM MgCl2, 1% 
TritonX-100, 1 mM PMSF), and analyzed by western blotting.
Double thymidine block synchronization
Cells were cultured with 2 mM thymidine (Sigma #T9250, 
http : //w w w.sigmaa ldrich.com/cata log/product /sigma /
t9250?lang=en&region=US) for 19 h, washed once with 1× PBS, 
incubated with fresh media without addition of thymidine, and 
then 2 mM thymidine was added back 8 h later. After another 
16 h, cells were washed once with 1× PBS, fresh media without 
thymidine addition was added back. Cells were collected every 2 
h and analyzed by western blotting.
DNA plasmids, siRNA, and lentiviral-based shRNA
All cloned constructs were confirmed by DNA sequencing. 
siRNA duplexes targeting APC2 (5′-AACGATCTGC 
AGGCCAACAT C-3′) and nonspecific control siRNA 
(5′-CAGUCGCGUU UGCGACUGG-3′) were manufactured 
by Dharmacon. Stealth siRNAs targeting APC2 (HSS121004, 
HSS179082, HSS179083, http://www.lifetechnologies.
com /order /genome-dat aba se /browse / s i rna /key word /
HSS121004) were manufactured by Invitrogen. Lenti-viral 
based shRNA clones were purchased commercially from Open 
Biosystems (pLKO.1 shRNA sets RMM4534-NM_175300, 
http://www.thermoscientif icbio.com/shrna/trc-lentiviral-
s h r n a / ? p r o du c t Id = 19 61 A 1D5 -D 4 C1- 4 A 2 3 - A 7 D 0 -
81D8B30525CB). Transfections of siRNA were performed with 
RNAiMax (Invitrogen # 13778, https://www.lifetechnologies.
com/order/catalog/product/13778075?ICID=search-product) 
according to the manufacturer’s instructions 48 h before 
additional treatments
SDS-page and western blotting
Cells were lysed in 0.5% NP-40 lysis buffer (50 mM TRIS-HCl 
pH7.5, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM NaVO3, 
1 mM DTT, 1 mM PMSF, 1× protease inhibitor cocktail), lysates 
were resolved on a 12.5% polyacrylamide gel and transferred onto 
a 0.45 µM nitrocellulose membrane. Membranes were blocked for 
at least 30 min in blocking buffer (PBS with 0.1% Tween-20 and 
5% nonfat dried milk). Membranes were incubated for overnight 
in primary antibody diluted in blocking buffer, incubated for 
1–2 h in secondary HRP-conjugated antibody diluted in block 
buffer, and exposed after incubate in Supersignal West Pico 
(Pierce #34080, http://www.piercenet.com/product/supersignal-
west-pico-chemiluminescent-substrate) or Dura (Pierce #37075, 
http://www.piercenet.com/product/supersignal-west-dura-
chemiluminescent-substrate) for 5 min.
IP-western blotting
MEF cells were lysed in 0.5% NP-40 lysis buffer. The 
lysates were pre-cleared with Sepharose CL4B beads (Sigma 
#CL4B200, http://www.sigmaaldrich.com/catalog/product/
sigma/cl4b200?lang=en&region=US) for 30 min and then 
immunoprecipitated with the specified antibody overnight at 
4 °C, followed by incubation with protein A/G beads (Pierce 
#20333, http://www.piercenet.com/product/protein-a-agarose), 
(Pierce #20399, http://www.piercenet.com/product/protein-g-
agarose-kits) for 2 h at 4° C. The beads were washed 4 times with 
cold 0.5% NP-40 lysis buffer, and analyzed by SDS-PAGE and 
western blotting.
Half-life assay
Cells were treated with cycloheximide (100–150 μg/mL) 
(Sigma #C7698, http://www.sigmaaldrich.com/catalog/product/
sigma/c7698?lang=en&region=US) for the indicated length of 
time and then harvested using 1× SDS lysis buffer (50 mM TRIS-
HCl, pH 7.5, 0.5 mM EDTA, 1% SDS, and 1 mM DTT). The 
Mdm2 level was analyzed by western blotting, and the intensity 
of the bands in the linear range of exposure was quantified by 
densitometry and normalized to Actin using ImageJ.
Beta-gal staining
Beta-Gal staining was done with Senescence β-Galactosidase 
Staining Kit (Cell Signaling #9860, http://www.cellsignal.com/
product/productDetail.jsp?productId=9860) according to the 
manufacturer’s instructions.
Luciferase assay
Beta-Gal staining was done with Dual-Light® Luciferase and 
β-Galactosidase Reporter Gene Assay System (Life technologies 
#T1004, http://www.lifetechnologies.com/order/catalog/
product/T1004?CID=bnk) according to the manufacturer’s 
instructions.
Antibodies
Rabbit anti-APC2 antibody was kindly provided by Dr Yue 
Xiong (UNC at Chapel Hill). HA (12CA5), myc (9E10), Mdm2 
(2A10), and Mdm2 (4B11) antibodies were made from the culture 
medium of the hybridoma cell line. The following antibodies were 
purchased commercially: Actin (Chemicon #MAB1501, http://
www.millipore.com/catalogue/item/mab1501), hp53 (DO-1 
Labvision AB-6 #MS-187 – P, http://www.fishersci.com/ecomm/
servlet/fsproductdetail_10652_1672983__-1_0), mp53 (Leica 
# NCL-p53–505, http://www.leicabiosystems.com/ihc-ish/
novocastra-reagents/primary-antibodies/details/product/p53-
protein/), FLAG (M2 Sigma #F3165, http://www.sigmaaldrich.
com/catalog/product/sigma/f3165?lang=en&region=US). 
Anti-UB (Covance #PRB-268C, https://store.crpinc.com/
datasheet.aspx?catalogno=prb-268C), Cyclin B1 (GNS1 Santa 
Cruz #sc-245, http://www.scbt.com/datasheet-245-cyclin-b1-
gns1-antibody.html)
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Figure 5 (See previous page). ApC2 downregulation correlates with cancer development. (A) Western blot was used to assess ApC2 and Mdm2 in JAR, 
HepG2, SJSA, MCF7, HeLa, A375, U2oS, and H1299 cancer cell lines. Actin was used as a loading control. (B) mRNA microarray data for ApC2 in Invasive 
breast carcinoma (Finak Breast), liver cancer with cirrhosis (Mas Liver), ductal breast carcinoma (Richardson Breast 2), and unspecified peripheral t-cell 
lymphoma (piccaluga Lymphoma). Data was obtained from oncomine. (C) tCGA Gene copy number data for ApC2 in breast, ovarian, lung, thyroid, liver, 
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